Fresenius Kabi Hit With Two Warning Letters At Sites In India In December
New Year’s resolutions anyone? Generic drug maker Fresenius Kabi closed out the year with the unlucky distinction of receiving not one – but two – drug GMP warning letters from FDA last month. The agency chastised the firm for not reporting failing test results and not getting to the root cause of sterility failures. The firm was also criticized for not learning from earlier mistakes.
You may also be interested in...
Hiding Cancer Drug Manufacturing Records Costs Fresenius Kabi $50M In US Settlement
It turns out there’s a price to pay for removing computers and chromatography instruments so their data can’t be inspected.
The Next New Thing In FDA Inspections: Poor Root Cause Investigations
Data integrity failures are so yesterday. Now it’s all about poor investigations into out-of-specification results.
FDA Warns Apotex Management To Demand Quality, Meet Specs
Apotex warning letter reflects FDA’s emphasis on company-wide quality systems and invalidated OOS results.